Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

"Prehistoric relics" as targets for vaccination against cancer

02.09.2013
Researchers at the Paul-Ehrlich-Institut have succeeded in using a peculiarity of cancer cells for targeted immunological attack: While endogenous retroviruses are inactive in healthy cells, cancer cells produce proteins of these viruses.

With a vaccine directed against endogenous retroviruses, the progression of tumour growth could be significantly inhibited in a mouse model. The prophylactic vaccination could even prevent the development of tumours. The results of this research project were reported in the online edition of PLoS ONE dated 30 August 2013 (11 p.m. CET).


The murine renal carcinoma cell line Renca. On the left: without HERV-K envelope protein expression. On the right: genetically modified Renca cells with HERV-K envelope protein (in red).


Source: PEI - The image is available with 300 dpi (4,7x13,7 cm) - please ask the PEI Press and information office

Human endogenous retroviruses (HERV) entered the human genome millions of years ago and have been passed on from generation to generation. The human genome contains several thousand such endogenous retrovirus genes. As a rule, the genes of HERV are mute, i.e. they do not produce proteins. Researchers of the Paul-Ehrlich-Institut and other groups have already been able to show that an increase in expression of genes of one group of these retroviruses occurs in HIV infected individuals but also in the tumour cells of various types of cancer. The HERV group could be identified as HERV-K/HML-2(hom), or for short, HERV-K. Professor Dr Barbara Schnierle and her co-workers in the Virology Division of the Paul-Ehrlich-Institut now wanted to know whether the specific gene activity of HERV-K could be used therapeutically to fight cancer cells in a targeted manner. To protect healthy cells, it is required to identify structures as targets which are only displayed on cancer cells.

For their investigations, Professor Barbara Schnierle, head of the Section "AIDS, New and Emerging Pathogens", and her co-workers used a murine kidney cell line (Renca). This cell line had been genetically modified in such a way that the cells produced (human) HERV-K envelope proteins to emulate the situation of the HERV-positive human cancer cells as accurately as possible. Mice which received an i.v. administration of these cells developed lung metastases within a short period of time.

For the "vaccination" against these tumours, the researchers used the modified vaccinia virus Ankara (MVA), an attenuated virus which cannot replicate after inoculation. In addition, Professor Schnierle and her co-workers had inserted the gene for the HERV-K envelope protein into the MVA genome. After the inoculation, the gene is read in the cells and the envelope protein is formed. It is presented to the immune system as antigen and an immune response can be induced.

Then the PEI scientists performed investigations to establish whether their "vaccine" could be used both for therapeutic and for prophylactic purposes: For the therapeutic approach, they first injected the genetically modified mouse cancer cells, then waited ten days until lung metastases were formed and then treated part of the mice with the MVA vaccine. The tumours grew considerably more slowly in the vaccinated animals and fewer metastases were observed than in the non-vaccinated animals. However, complete tumour remission was not achieved.

With regard to the prophylactic vaccination, the effect was even more significant: Here, the animals were at first vaccinated twice with the virus (days 0 and 21), and the cancer cells were administered twelve days later. The animals thus vaccinated were protected entirely from tumour development – no metastases could be identified.

"The findings have shown for the first time that the HERV-K envelope protein could be a useful target for the development of a vaccine, and may be able to provide new options for the treatment of various tumours" explained Professor Schnierle.

The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines in Langen in the federal state of Hessen, is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and veterinary vaccines. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects. Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the varied and many tasks performed at the institute. The PEI, with its roughly 800 staff, also has advisory functions at a national level (federal government, federal states (Länder)), and at an international level (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.).

Weitere Informationen:

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0072756 Publication (Fulltext)

http://www.pei.de/EN/information/journalists-press/press-releases/2013/04-prehistoric-relics-targets-vaccination-against-cancer.html

Press Release on the PEI-Website

Dr. Susanne Stöcker | idw
Further information:
http://www.pei.de

More articles from Life Sciences:

nachricht Link Discovered between Immune System, Brain Structure and Memory
26.04.2017 | Universität Basel

nachricht Researchers develop eco-friendly, 4-in-1 catalyst
25.04.2017 | Brown University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Scientist invents way to trigger artificial photosynthesis to clean air

26.04.2017 | Materials Sciences

Ammonium nitrogen input increases the synthesis of anticarcinogenic compounds in broccoli

26.04.2017 | Agricultural and Forestry Science

SwRI-led team discovers lull in Mars' giant impact history

26.04.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>